Skinbiotherapeutics Share Discussion Threads

[ibug] 23/5/2017 10:13

Galashiels 23 May '17 - 10:04 - 393 of 393 0 0 (Filtered)

NOT APPLICABLE TO THIS STOCK imo

[galashiels] 23/5/2017 10:04

AIM Listed:

If these guys are behind any AIM listed company, people should look at the dilution history of that company, in general they may find dilution - consolidation - dilution pattern, no matter how good the company, if you are going to keep getting diluted to keep a company afloat, what's the point, It's you who are feeding money to them, source of income is shareholders.

Cairn Financial Advisers LLP
www.londonstockexchange.com/exchange/companies-and-advisors/aim/for-companies/nomad-broker-profile.html?nomadBrokerId=312

WH Ireland Limited
www.londonstockexchange.com/exchange/companies-and-advisors/aim/for-companies/nomad-broker-profile.html?nomadBrokerId=101

Hybridan LLP
www.londonstockexchange.com/exchange/companies-and-advisors/aim/for-companies/nomad-broker-profile.html?nomadBrokerId=290

Daniel Stewart & Company Plc
www.londonstockexchange.com/exchange/companies-and-advisors/aim/for-companies/nomad-broker-profile.html?nomadBrokerId=134

Northland Capital Partners
www.londonstockexchange.com/exchange/companies-and-advisors/aim/for-companies/nomad-broker-profile.html?nomadBrokerId=22

Do go back and check those penny stocks that you may have been diluted out in the past, were these guys behind those companies too?

Feel free to copy this post and post it on any thread that you deem proper to highlight the issue of small investors getting screwed time after time.

[ibug] 23/5/2017 10:03

We are looking at product development this year and commercialization in 2018...looks like the development plan is progressing well imo.

Once the safety certificate has been awarded then clinical trials can start.


Todays news suggests the development plan is rolling out imo.

[onedayrodders] 23/5/2017 09:55

Although I agree it's underwhelming why would you NOT expect similar RNS to OPTI ?!?!

It's the same science ..and it's at a very early stage

[scotty1] 23/5/2017 09:35

Hope it's not going to do the same RNSs as OPTI for the next year or so,all Jam tomorrow stuff.

[rafboy] 23/5/2017 09:28

Yes, timescale for commercialisation is longer than perhaps we first thought. However, we know the importance of having the science right behind us.

[monkeywench1] 23/5/2017 09:27

RNS Number : 8748F

SkinBioTherapeutics PLC

23 May 2017

SkinBioTherapeutics plc

(the "Company")

Extension of research contract with University of Manchester

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that, as envisaged in the Company's Admission Document dated 29 March 2017, it has agreed an eight month extension to its research contract with the University of Manchester to June 2018. This contract extension includes provision for the appointment of a second technician to the Company. This will increase the Company's ability to develop its SkinBiotix(R) platform.

Furthermore, the Company announces that it has recently demonstrated activity of SkinBiotix(R) at a range of doses in human skin models, and also completed the design of two human safety trials. If successful, these trials will allow the technology to be labelled 'dermatologically tested' for its cosmetic application.

Dr. Catherine O'Neill, CEO of SkinBioTherapeutics, said:

"We are making progress in our research, and the extension and expansion of our contract with the University of Manchester will allow meaningful progression across the Company. We are pleased with the progress of SkinBiotix, and are confident that it remains on track.

"As a team, we have nurtured relationships with industry stakeholders for many years. Since our IPO, we have continued to ensure potential commercial partners are aware of the capabilities of the SkinBiotix platform."

[judijudi] 23/5/2017 09:26

I personally found it very underwhelming

[rafboy] 23/5/2017 09:20

Seems a positive RNS so surprised to see us down.

[judijudi] 23/5/2017 09:19

No deal anytime soon then by the tone of that statement

[bdog51] 23/5/2017 08:03

RNS 23rd May: Extension of Research Contract

Extension of research contract with University of Manchester

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that, as envisaged in the Company's Admission Document dated 29 March 2017, it has agreed an eight month extension to its research contract with the University of Manchester to June 2018. This contract extension includes provision for the appointment of a second technician to the Company. This will increase the Company's ability to develop its SkinBiotix® platform.

Furthermore, the Company announces that it has recently demonstrated activity of SkinBiotix® at a range of doses in human skin models, and also completed the design of two human safety trials. If successful, these trials will allow the technology to be labelled 'dermatologically tested' for its cosmetic application.

Dr. Catherine O'Neill, CEO of SkinBioTherapeutics, said:

"We are making progress in our research, and the extension and expansion of our contract with the University of Manchester will allow meaningful progression across the Company. We are pleased with the progress of SkinBiotix, and are confident that it remains on track.

"As a team, we have nurtured relationships with industry stakeholders for many years. Since our IPO, we have continued to ensure potential commercial partners are aware of the capabilities of the SkinBiotix platform."

[parob] 22/5/2017 19:56

SkinBioTherapeutics 'starting early conversations with potential commercial partners'

16:05 22 May 2017

Dr Cath O'Neill, chief executive of SkinBioTherapeutics plc (LON:SBTX) tells Proactive it's been a very busy and exciting time for them since IPO'ing on 5 April 2017.

''We've been concentrating on further development of our technology and starting some early conversations with potential commercial partners''.

[slartybartfaster] 22/5/2017 11:39

Good volume again.

[monkeywench1] 21/5/2017 21:06

lukead

Lol.

[elrico] 20/5/2017 15:48

Or this I posted - 10 Dec 2016

Johnson & Johnson Innovation team up with Manchester scientists Since 19 Jun 2014
As part of a strategy to explore the emerging science around the human microbiome and its impact across several areas of health and disease, Johnson & Johnson Consumer & Personal Products Worldwide and Johnson & Johnson Innovation have established a collaboration with scientists from The University of Manchester.
The collaboration will explore potential applications of probiotic extracts for prevention and treatment of skin, oral, and respiratory conditions.
Dr Catherine ONeill, from the University's Institute of Inflammation and Repair, and Dr Andrew McBain, from Manchester Pharmacy School, will lead on the research project with Johnson & Johnson Innovation.

Dr O'Neill said: It's exciting to be working with such a massive global player who we hope will really help us to develop products which will bring benefits to patients.

"This collaboration will help us co-develop a piece of technology established here in Manchester which uses probiotics" or friendly bacteria - on the skin and hopefully take this to market.

The agreement underscores the approach Johnson & Johnson Innovation is taking to establish scientific collaborations in areas that span its pharmaceutical, medical device and diagnostics and consumer businesses.

[lukead] 20/5/2017 15:13

Once a Troll, always a Troll. All he can manage is 1 line and sometimes just 1 word. Spending so much time on calling everyone who post's something of interest, a ramper. Monkeywench1, seemingly of low intelligence can not come up with any meaningful debate, hence the 1 word/1line post of scorn.

[slartybartfaster] 20/5/2017 15:08

someuwin, you can now ban the monkey now is no long a premium member.

[incanus] 20/5/2017 14:04

I cant find the post or poster but i found this.

someuwin - 27 Feb 2015 - 14:11:56 - 591 of 23861 OptiBiotix - Better Science, Better Health. Better buy some! - OPTI
There's a land grab going on in this niche sector.

Johnson & Johnson and Nestle have both made multi million $ moves already this year.

This new science is red hot and there will be many big names looking at OPTI.

[incanus] 20/5/2017 11:40

Someone else mentioned the johnson & johnson and alliance boots were established around the same time. I wonder if both collaborations could yield commercial terms by late 2018? They also mentioning johnson & johnson had done a lot of work with uom, on this basis it would be hard to see them walk away after investing time and money without it proving productive. Sorry but i can't recall who it was.

[parob] 20/5/2017 10:14

Trotters mentioned the UOM/J&J link earlier in the week, let's not forget UOM also have a relationship with Alliance Boots - another potential future partner for SBTX:



Alliance Boots and The University of Manchester renew partnership

17 Jul 2014

Five year skin research programme to help further develop the understanding of skin ageing.
Alliance Boots and The University of Manchester announce they have renewed their partnership in order to build on the highly successful work already achieved between the two organisations. This new five year partnership, which will run until the end of 2018, aims to further investigate the mechanisms by which human skin ages and, in turn, help boost innovation within Boots product brands.